Predicine to Present Four Studies at 2023 ASCO Genitourinary (GU) Symposium Highlighting the Technical and Clinical Utility of Predicine’s Liquid Biopsy Based Assays HAYWARD, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, is committed to advancing genitourinary (GU) cancer detection and treatment decisions through its...

Predicine to Introduce PredicineCOMPLETE™, its Genome-Wide Liquid Biopsy Solution, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting SILICON VALLEY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announces the introduction of PredicineCOMPLETE™, the organization’s most comprehensive...

Predicine Expands to Europe with the recently launched CE-Marked cfDNA Assay PredicineCARE™ for Genomic Profiling in Blood and Urine SILICON VALLEY, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company, has launched its CE-marked PredicineCARE™ for genomic profiling in blood and urine....